Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma

Open access

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with limited treatment options. Although metabolic reprogramming is a hallmark of many cancers, including PDA, previous attempts to target metabolic changes therapeutically have been stymied by drug toxicity and tumour cell plasticity. Here, we show that PDA cells engage an eIF4F-dependent translation program that supports redox and central carbon metabolism. Inhibition of the eIF4F subunit, eIF4A, using the synthetic rocaglate CR-1-31-B (CR-31) reduced the viability of PDA organoids relative to their normal counterparts. In vivo, CR-31 suppresses tumour growth and extends survival of genetically-engineered murine models of PDA. Surprisingly, inhibition of eIF4A also induces glutamine reductive carboxylation. As a consequence, combined targeting of eIF4A and glutaminase activity more effectively inhibits PDA cell growth both in vitro and in vivo. Overall, our work demonstrates the importance of eIF4A in translational control of pancreatic tumour metabolism and as a therapeutic target against PDA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-13086-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The eIF4A inhibitor CR-31 potently targets pancreatic ductal adenocarcinoma. a Normal (N), and KrasG12D;p53R172H (KP) organoids were treated with 10 nM CR-31 for 60 min and compared to vehicle (DMSO). During the last 30 min, 10 μM O-propargyl-puromycin (OP-Puro) was supplemented into the media. Dissociated single cells were fixed, stained by CuAAC with Alexa488-azide and the level of OP-Puro conjugation within polypeptide chains was quantified by flow cytometry. b Cell viability of N and KP organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate 95% confidence intervals (n = 5). Inset shows representative images of organoids treated with 10 nM CR-31 for 72 h. Scale bars, 1000 μm. c SUnSET assay of representative PDA tumours from mice following 7 daily treatments with vehicle (5.2% PEG-400/5.2% Tween80) or 0.2 mg kg−1 CR-31. Mice were euthanized for tissue collection 2 h after the final treatment with vehicle or CR-31 and 30 min after 40 nmol g−1 puromycin injection. Scale bars, 50 μm. d Relative tumour volume of PDA-bearing mice after 7 daily treatments with 0.2 mg kg−1 CR-31 or vehicle. Relative growth was estimated by comparison of tumour volume 7 days post injection to that at pre-enrolment (day 0) by ultrasound imaging. Data are mean +/– S.D. Student’s t-test. (n = 11, vehicle; n = 7, CR-31). e Immunohistochemistry of cleaved caspase 3 (left) in representative tumours from mice treated daily for 7 days with vehicle or 0.2 mg kg−1 CR-31 together with quantification of cleaved caspase 3 (right) from n ≥ 7 fields of view. Data are mean +/–S.D. Student’s t-test. Tissues were harvested 2 h post final treatment. Scale bars, 50 μm. f Kaplan–Meier survival analysis for KrasG12D;p53R172H;PdxCre (KPC) mice treated daily with vehicle (n = 13) or 0.2 mg kg−1 CR-31 (n = 16). Mantel-Cox (log rank) test. Source data are provided as a Source Data file
Fig. 1 The eIF4A inhibitor CR-31 potently targets pancreatic ductal adenocarcinoma. a Normal (N), and KrasG12D;p53R172H (KP) organoids were treated with 10 nM CR-31 for 60 min and compared to vehicle (DMSO). During the last 30 min, 10 μM O-propargyl-puromycin (OP-Puro) was supplemented into the media. Dissociated single cells were fixed, stained by CuAAC with Alexa488-azide and the level of OP-Puro conjugation within polypeptide chains was quantified by flow cytometry. b Cell viability of N and KP organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate 95% confidence intervals (n = 5). Inset shows representative images of organoids treated with 10 nM CR-31 for 72 h. Scale bars, 1000 μm. c SUnSET assay of representative PDA tumours from mice following 7 daily treatments with vehicle (5.2% PEG-400/5.2% Tween80) or 0.2 mg kg−1 CR-31. Mice were euthanized for tissue collection 2 h after the final treatment with vehicle or CR-31 and 30 min after 40 nmol g−1 puromycin injection. Scale bars, 50 μm. d Relative tumour volume of PDA-bearing mice after 7 daily treatments with 0.2 mg kg−1 CR-31 or vehicle. Relative growth was estimated by comparison of tumour volume 7 days post injection to that at pre-enrolment (day 0) by ultrasound imaging. Data are mean +/– S.D. Student’s t-test. (n = 11, vehicle; n = 7, CR-31). e Immunohistochemistry of cleaved caspase 3 (left) in representative tumours from mice treated daily for 7 days with vehicle or 0.2 mg kg−1 CR-31 together with quantification of cleaved caspase 3 (right) from n ≥ 7 fields of view. Data are mean +/–S.D. Student’s t-test. Tissues were harvested 2 h post final treatment. Scale bars, 50 μm. f Kaplan–Meier survival analysis for KrasG12D;p53R172H;PdxCre (KPC) mice treated daily with vehicle (n = 13) or 0.2 mg kg−1 CR-31 (n = 16). Mantel-Cox (log rank) test. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 2 Tumour-selective modulation of translational efficiencies by CR-31. a Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing vehicle-treated KrasG12D;p53R172H (KP) to normal (N) organoids. The numbers of mRNAs with a change in translation efficiency (light red and dark red) or mRNA abundance (light green and dark green) are indicated (n = 3; positive log2 fold-change indicates higher translation/abundance in KP organoids). b Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing N organoids treated with vehicle or 10 nM CR-31 for 1 h. The numbers of mRNAs with a change in translation efficiency (light red and dark red) are indicated (negative log2 fold-change indicates suppressed translation upon CR-31 treatment). c Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing KP organoids treated with vehicle or 10 nM CR-31 for 1 h. The numbers of mRNAs with a change in translation efficiency (light red and dark red) are indicated (negative log2 fold-changes indicates suppressed translation upon CR-31 treatment). d Scatterplot of log2 fold-changes for polysome-associated mRNA and total mRNA (left), an empirical cumulative distribution (ecdf) of log2 fold-changes for polysome-associated mRNA (middle) and total mRNA (right) comparing KP and N organoids. Transcripts whose translation was activated (light red) or suppressed (dark red) upon CR-31 treatment in KP organoids (i.e. from (c)) are indicated for each plot. Wilcoxon rank-sum test p-values comparing regulation of subsets to background are indicated together with the log2 fold-changes difference between these subsets to the background at the 50th percentile (q50) of the ecdf. e Same representation as in panel d but examining differences in gene expression in N organoids upon CR-31 treatment. Source data are provided as a Source Data file
Fig. 2 Tumour-selective modulation of translational efficiencies by CR-31. a Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing vehicle-treated KrasG12D;p53R172H (KP) to normal (N) organoids. The numbers of mRNAs with a change in translation efficiency (light red and dark red) or mRNA abundance (light green and dark green) are indicated (n = 3; positive log2 fold-change indicates higher translation/abundance in KP organoids). b Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing N organoids treated with vehicle or 10 nM CR-31 for 1 h. The numbers of mRNAs with a change in translation efficiency (light red and dark red) are indicated (negative log2 fold-change indicates suppressed translation upon CR-31 treatment). c Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing KP organoids treated with vehicle or 10 nM CR-31 for 1 h. The numbers of mRNAs with a change in translation efficiency (light red and dark red) are indicated (negative log2 fold-changes indicates suppressed translation upon CR-31 treatment). d Scatterplot of log2 fold-changes for polysome-associated mRNA and total mRNA (left), an empirical cumulative distribution (ecdf) of log2 fold-changes for polysome-associated mRNA (middle) and total mRNA (right) comparing KP and N organoids. Transcripts whose translation was activated (light red) or suppressed (dark red) upon CR-31 treatment in KP organoids (i.e. from (c)) are indicated for each plot. Wilcoxon rank-sum test p-values comparing regulation of subsets to background are indicated together with the log2 fold-changes difference between these subsets to the background at the 50th percentile (q50) of the ecdf. e Same representation as in panel d but examining differences in gene expression in N organoids upon CR-31 treatment. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 3 CR-31 translationally targets glutathione metabolism in PDA. a Heatmap of glutathione metabolism pathway proteins (KEGG database) showing fold-changes of polysome-associated mRNA. b Relative levels of NADPH normalized to viability based on CellTitre-Glo (CTG) assay (left) and ratio of NADP+ to NADPH (right) in organoids and patient-derived PDA lines upon treatment with vehicle (DMSO) or 100 nM CR-31 for 16 h. Data are mean +/–S.D. Student’s t-test, n = 4 (organoids), n = 5 (patient-derived lines). NS = not significant. c Relative levels of glutathione in patient-derived PDA lines upon treatment with vehicle or CR-31 for 24 h. Data are mean +/–S.D., Student’s t-test. n = 5, NS = not significant. *p < 0.05 compared to DMSO treatment. d Ratio of GSH to GSSG in patient-derived PDA lines upon treatment with vehicle or the indicated concentrations of CR-31 for 24 h. Data are mean +/–S.D., Student’s t-test, n = 5. *p < 0.05 compared to DMSO treatment. e ROS levels in KP organoids upon treatment with vehicle or 10 nM CR-31 for 16 h. Data are representative from three biological replicates. f NRF2 protein levels in KP organoids treated with CR-31 for 16 h. Actin, loading control. Representative image from 3 biological replicates. g mRNA expression of NRF2 target genes in 3 patient-derived PDA lines upon treatment with CR-31 for 5 or 24 h. Data are mean +/–S.D. Each data point plotted is average from every biological replicate. h Cell viability of KP and Nrf2-deficient KP (KPn) organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate 95% confidence intervals, n = 5. i Cell viability of patient-derived PDA lines upon treatment with increasing concentrations of CR-31 in the presence or absence of 100 μM buthionine sulfoximine (BSO) for 72 h. Data are mean +/–S.D., n = 5. j Cell viability of primary murine PDA lines upon treatment with increasing concentrations of CR-31 in the presence or absence of 1 mM of the ROS scavenger N-acetylcysteine (NAC) for 72 h. Data are mean +/–S.D., n = 3. Source data are provided as a Source Data file
Fig. 3 CR-31 translationally targets glutathione metabolism in PDA. a Heatmap of glutathione metabolism pathway proteins (KEGG database) showing fold-changes of polysome-associated mRNA. b Relative levels of NADPH normalized to viability based on CellTitre-Glo (CTG) assay (left) and ratio of NADP+ to NADPH (right) in organoids and patient-derived PDA lines upon treatment with vehicle (DMSO) or 100 nM CR-31 for 16 h. Data are mean +/–S.D. Student’s t-test, n = 4 (organoids), n = 5 (patient-derived lines). NS = not significant. c Relative levels of glutathione in patient-derived PDA lines upon treatment with vehicle or CR-31 for 24 h. Data are mean +/–S.D., Student’s t-test. n = 5, NS = not significant. *p < 0.05 compared to DMSO treatment. d Ratio of GSH to GSSG in patient-derived PDA lines upon treatment with vehicle or the indicated concentrations of CR-31 for 24 h. Data are mean +/–S.D., Student’s t-test, n = 5. *p < 0.05 compared to DMSO treatment. e ROS levels in KP organoids upon treatment with vehicle or 10 nM CR-31 for 16 h. Data are representative from three biological replicates. f NRF2 protein levels in KP organoids treated with CR-31 for 16 h. Actin, loading control. Representative image from 3 biological replicates. g mRNA expression of NRF2 target genes in 3 patient-derived PDA lines upon treatment with CR-31 for 5 or 24 h. Data are mean +/–S.D. Each data point plotted is average from every biological replicate. h Cell viability of KP and Nrf2-deficient KP (KPn) organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate 95% confidence intervals, n = 5. i Cell viability of patient-derived PDA lines upon treatment with increasing concentrations of CR-31 in the presence or absence of 100 μM buthionine sulfoximine (BSO) for 72 h. Data are mean +/–S.D., n = 5. j Cell viability of primary murine PDA lines upon treatment with increasing concentrations of CR-31 in the presence or absence of 1 mM of the ROS scavenger N-acetylcysteine (NAC) for 72 h. Data are mean +/–S.D., n = 3. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 CR-31 translationally targets oxidative phosphorylation and glycolysis in PDA. a Heatmap of oxidative phosphorylation pathway proteins showing fold-changes of polysome-associated mRNA. b Boxplots of total and polysome-associated mRNA levels for transcripts encoding oxidative phosphorylation components. Horizontal line indicates the median; lower and upper box indicate the first and third quartiles. Whiskers extend from the box to the most extreme value but not further than +/−1.5 * inter-quartile range (IQR) from the box. Data exceeding the whiskers are plotted as points. b 13C6-glucose tracing of N (n = 2) and KP organoids (n = 4). M +2 labelled citrate is derived directly from 13C6-glucose. Data are mean +/– S.D., Student’s t-test. c Mitochondrial respiration reflected by oxygen consumption rate (OCR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following the addition of Oligomycin (1 μM), the uncoupler FCCP (0.5 μM), and the electron transport inhibitor Rotenone/Antimycin A (0.5 μM). Data are mean +/– S.D, n = 3. Data are representative from three biological replicates. d OCR was measured in N organoids treated with vehicle CR-31 for 5 h and following the addition of Oligomycin, FCCP, and Rotenone/Antimycin A. Data are mean +/– S.D. n = 5. Data are representative from three biological replicates. e Top, flow of heavy carbons through the glycolytic pathway. Bottom, 13C6-glucose tracing of two sets of N and KP organoids (left) and 4 patient-derived PDA cell lines (middle and right) upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. f Glycolysis reflected by extracellular acidification rate (ECAR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following addition of glucose (10 mM), Oligomycin (1 μM), and the glucose analog, 2-deoxyglucose, 2DG (50 mM). Data are mean +/– S.D., n = 3. Data are representative of three biological replicates. g ECAR was measured in N organoids treated with vehicle or CR-31 for 5 h and following addition of glucose, Oligomycin, and 2DG. Data are mean +/– S.D., n = 5. Data are representative of three biological replicates. Source data are provided as a Source Data file
Fig. 4 CR-31 translationally targets oxidative phosphorylation and glycolysis in PDA. a Heatmap of oxidative phosphorylation pathway proteins showing fold-changes of polysome-associated mRNA. b Boxplots of total and polysome-associated mRNA levels for transcripts encoding oxidative phosphorylation components. Horizontal line indicates the median; lower and upper box indicate the first and third quartiles. Whiskers extend from the box to the most extreme value but not further than +/−1.5 * inter-quartile range (IQR) from the box. Data exceeding the whiskers are plotted as points. b 13C6-glucose tracing of N (n = 2) and KP organoids (n = 4). M +2 labelled citrate is derived directly from 13C6-glucose. Data are mean +/– S.D., Student’s t-test. c Mitochondrial respiration reflected by oxygen consumption rate (OCR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following the addition of Oligomycin (1 μM), the uncoupler FCCP (0.5 μM), and the electron transport inhibitor Rotenone/Antimycin A (0.5 μM). Data are mean +/– S.D, n = 3. Data are representative from three biological replicates. d OCR was measured in N organoids treated with vehicle CR-31 for 5 h and following the addition of Oligomycin, FCCP, and Rotenone/Antimycin A. Data are mean +/– S.D. n = 5. Data are representative from three biological replicates. e Top, flow of heavy carbons through the glycolytic pathway. Bottom, 13C6-glucose tracing of two sets of N and KP organoids (left) and 4 patient-derived PDA cell lines (middle and right) upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. f Glycolysis reflected by extracellular acidification rate (ECAR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following addition of glucose (10 mM), Oligomycin (1 μM), and the glucose analog, 2-deoxyglucose, 2DG (50 mM). Data are mean +/– S.D., n = 3. Data are representative of three biological replicates. g ECAR was measured in N organoids treated with vehicle or CR-31 for 5 h and following addition of glucose, Oligomycin, and 2DG. Data are mean +/– S.D., n = 5. Data are representative of three biological replicates. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 5 CR-31 translationally targets glucose uptake in PDA. a Levels of transcripts encoding glycolytic proteins in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to vehicle. Data are mean +/− S.D. n = 6. b Immunoblot analysis of SLC2A6, ENOLASE 1, ENOLASE2, ENOLASE 3, and GAPDH in N and KP organoids upon vehicle or CR-31 treatment for 5 h. Vinculin, loading control. c Immunoblot analysis of SLC2A6, ENOLASE1, ENOLASE2, ENOLASE3, and GAPDH in patient-derived PDA lines upon vehicle or CR-31 treatment. VINCULIN, loading control. d Glucose concentration in media spent from KP organoids upon treatment with vehicle or CR-31. Data are mean +/− S.D., Student’s t-test, n = 3. *p < 0.05, compared to DMSO treatment at the same timepoint. e Representative 18F-FDG-PET images of pancreatic tumours from mice after 24 h of treatment with vehicle or CR-31. Top, coronal view; bottom, transverse view. f Tumour uptake plots comparing initial metabolic activity before and after treatment with vehicle or CR-31. Left, maximum standardized uptake value (SUV)max of tumour. Right, ratio of (SUV)max in tumour compared to muscles. Data are mean +/− S.D., Student’s t-test. n = 7, Vehicle; n = 8, CR-31. g Glucose uptake comparing Cas9-expressing murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or against different regions of the Slc2a6 gene (sgSlc2a6). Data are mean +/− S.D., normalized to cell numbers. Student’s t-test, n = 4. h ECAR was measured in equal numbers of Cas9-expressing primary murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 5. i ECAR was measured in equal numbers of Cas9-expressing KP organoids transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 6. Source data are provided as a Source Data file
Fig. 5 CR-31 translationally targets glucose uptake in PDA. a Levels of transcripts encoding glycolytic proteins in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to vehicle. Data are mean +/− S.D. n = 6. b Immunoblot analysis of SLC2A6, ENOLASE 1, ENOLASE2, ENOLASE 3, and GAPDH in N and KP organoids upon vehicle or CR-31 treatment for 5 h. Vinculin, loading control. c Immunoblot analysis of SLC2A6, ENOLASE1, ENOLASE2, ENOLASE3, and GAPDH in patient-derived PDA lines upon vehicle or CR-31 treatment. VINCULIN, loading control. d Glucose concentration in media spent from KP organoids upon treatment with vehicle or CR-31. Data are mean +/− S.D., Student’s t-test, n = 3. *p < 0.05, compared to DMSO treatment at the same timepoint. e Representative 18F-FDG-PET images of pancreatic tumours from mice after 24 h of treatment with vehicle or CR-31. Top, coronal view; bottom, transverse view. f Tumour uptake plots comparing initial metabolic activity before and after treatment with vehicle or CR-31. Left, maximum standardized uptake value (SUV)max of tumour. Right, ratio of (SUV)max in tumour compared to muscles. Data are mean +/− S.D., Student’s t-test. n = 7, Vehicle; n = 8, CR-31. g Glucose uptake comparing Cas9-expressing murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or against different regions of the Slc2a6 gene (sgSlc2a6). Data are mean +/− S.D., normalized to cell numbers. Student’s t-test, n = 4. h ECAR was measured in equal numbers of Cas9-expressing primary murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 5. i ECAR was measured in equal numbers of Cas9-expressing KP organoids transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 6. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 6 CR-31 treatment increases reverse glutamine metabolism in pancreatic cancer cells. a Levels of transcripts encoding proteins involved in glutamine metabolism in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to vehicle (DMSO). Data are mean +/– S.D., n = 6. Data from two biological replicates are shown. b Immunoblot analysis of GLS in patient-derived PDA cell lines upon treatment with vehicle or CR-31 for 5 h. VINCULIN, TUBULIN, loading controls. c Intracellular levels of glutamine at steady state from 3 patient-derived PDA cell lines (2 technical replicates each) treated with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. d 13C5-glutamine tracing of 4 patient-derived PDA cell lines upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. Right, schematic illustrating the flow of heavy carbons through glutamine metabolic pathways. e 13C5-glutamine tracing of 4 patient-derived PDA cell lines upon treatment with vehicle or 100 nM CR-31 for 5 h. M + 4 indicates metabolites of oxidative glutaminolysis and M + 5 indicates metabolites of reductive glutaminolysis. Data are mean +/– S.D., Student’s paired t-test. f 13C5-glutamine tracing of N (n = 2) and KP (n = 2) organoids upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s t-test. g Cell viability of patient-derived PDA lines upon a 72 h treatment with increasing concentrations of CR-31 and the indicated concentrations of the glutaminase inhibitor BPTES (n = 5) or CB839 (n = 3). Data are mean +/– S.D., Student’s t-test, *p < 0.05 compared to CR-31 only treatment. h Cell viability of KP organoids upon a 72 h treatment with increasing concentrations of CR-31 and the indicated concentrations of CB839. Dotted lines indicate 95% confidence intervals, n = 5. i KP organoids (GFP-labelled) in co-culture with pancreatic cancer-associated fibroblasts (mCherry-labelled) upon a 72 h treatment with CR-31 in the presence or absence of CB839. Representative images from two biological replicates. Scale bars, 1000 μm. Source data are provided as a Source Data file
Fig. 6 CR-31 treatment increases reverse glutamine metabolism in pancreatic cancer cells. a Levels of transcripts encoding proteins involved in glutamine metabolism in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to vehicle (DMSO). Data are mean +/– S.D., n = 6. Data from two biological replicates are shown. b Immunoblot analysis of GLS in patient-derived PDA cell lines upon treatment with vehicle or CR-31 for 5 h. VINCULIN, TUBULIN, loading controls. c Intracellular levels of glutamine at steady state from 3 patient-derived PDA cell lines (2 technical replicates each) treated with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. d 13C5-glutamine tracing of 4 patient-derived PDA cell lines upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s paired t-test. Right, schematic illustrating the flow of heavy carbons through glutamine metabolic pathways. e 13C5-glutamine tracing of 4 patient-derived PDA cell lines upon treatment with vehicle or 100 nM CR-31 for 5 h. M + 4 indicates metabolites of oxidative glutaminolysis and M + 5 indicates metabolites of reductive glutaminolysis. Data are mean +/– S.D., Student’s paired t-test. f 13C5-glutamine tracing of N (n = 2) and KP (n = 2) organoids upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean +/– S.D., Student’s t-test. g Cell viability of patient-derived PDA lines upon a 72 h treatment with increasing concentrations of CR-31 and the indicated concentrations of the glutaminase inhibitor BPTES (n = 5) or CB839 (n = 3). Data are mean +/– S.D., Student’s t-test, *p < 0.05 compared to CR-31 only treatment. h Cell viability of KP organoids upon a 72 h treatment with increasing concentrations of CR-31 and the indicated concentrations of CB839. Dotted lines indicate 95% confidence intervals, n = 5. i KP organoids (GFP-labelled) in co-culture with pancreatic cancer-associated fibroblasts (mCherry-labelled) upon a 72 h treatment with CR-31 in the presence or absence of CB839. Representative images from two biological replicates. Scale bars, 1000 μm. Source data are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 107

Metadata

Authors
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C. J., Brown, L. E., Porco, J. A., Pollak, M., Larsson, O., Pelletier, J., & Chio, I. I. C.
Affiliations
  • Columbia University Irving Medical Center (US)
  • McGill University (CA)
  • Karolinska Institutet (SE)
  • Cold Spring Harbor Laboratory (US)
  • University of Pennsylvania (US)
  • National Cancer Institute (US)
  • Boston University (US)
Corresponding author
  • Larsson, Ola
  • Pelletier, Jerry
  • Chio, Iok In Christine
Venue
Nature Communications
Published
2019-11-13
Volume
10
Issue
1
Pages
5151-5151
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2988312256
Cited by
106
References
70
Citations by year
2026: 5 · 2025: 12 · 2024: 20 · 2023: 20 · 2022: 16 · 2021: 24 · 2020: 9
FWCI
5.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • OpenBU (Boston University) (submittedVersion)
Funders
  • Pancreatic Cancer Action Network (PANCAN 18-35-CHIO)
  • V Foundation for Cancer Research (VFND V2018-017)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
eIF4A, pancreatic ductal adenocarcinoma, eIF4F, translational regulation, metabolic reprogramming, rocaglates, glutaminase, cancer metabolism, oncogenic translation, tumor organoids, anticancer drug targets
MeSH terms
Animals, Glutathione, Humans, Mice, Inbred C57BL, Oxidation-Reduction, Pancreatic Neoplasms, Protein Biosynthesis, Carcinoma, Pancreatic Ductal, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, Molecular Targeted Therapy, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1038/s41467-019-13086-5
The paper
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C. J., Brown, L. E., Porco, J. A., Pollak, M., Larsson, O., . . . Chio, I. I. C. (2019). eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications. https://doi.org/10.1038/s41467-019-13086-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.